Comparative Pharmacology
Head-to-head clinical analysis: ARANESP versus OMONTYS PRESERVATIVE FREE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ARANESP versus OMONTYS PRESERVATIVE FREE.
ARANESP vs OMONTYS PRESERVATIVE FREE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Aranesp (darbepoetin alfa) is an erythropoiesis-stimulating agent (ESA) that stimulates erythropoiesis by binding to the erythropoietin receptor on erythroid progenitor cells, promoting their survival, proliferation, and differentiation into mature red blood cells.
Epoetin alfa-epbx is a recombinant human erythropoietin that stimulates erythropoiesis by binding to and activating the erythropoietin receptor on erythroid progenitor cells, promoting their survival, proliferation, and differentiation.
Initial dose 0.45 mcg/kg intravenously or subcutaneously once weekly; for patients converting from epoetin alfa, see prescribing information for dose conversion.
The recommended dose of OMONTYS (pegcetacoplan) for paroxysmal nocturnal hemoglobinuria (PNH) is 1080 mg subcutaneously twice weekly via a proprietary infusion pump.
None Documented
None Documented
The terminal elimination half-life is approximately 21 hours (range 15-30 hours) in patients with chronic kidney disease following intravenous administration, and 49 hours (range 27-89 hours) after subcutaneous administration. The long half-life allows for less frequent dosing compared to epoetin alfa.
Terminal elimination half-life is approximately 24–30 hours in patients with chronic kidney disease on dialysis; longer half-life may occur in patients with residual renal function.
Renal clearance accounts for approximately 10% of total body clearance; however, darbepoetin alfa is primarily eliminated via receptor-mediated endocytosis and subsequent intracellular degradation. Less than 5% is excreted unchanged in urine.
Primarily renal: approximately 60% of the dose excreted unchanged in urine; biliary/fecal elimination is a minor route (<10%).
Category C
Category C
Erythropoiesis-Stimulating Agent
Erythropoiesis-Stimulating Agent